SAN DIEGO – June 23, 2022 – Vividion Therapeutics, Inc., a biopharmaceutical business making use of unique discovery innovations to open high worth, generally undruggable targets with accuracy therapies for ravaging cancers and immune conditions, and a completely owned and individually ran subsidiary of Bayer AG, today revealed that Aleksandra Rizo, M.D., Ph.D., will sign up with the business as President and Head of Research and Development. Dr. Rizo brings comprehensive market management experience to Vividion, having actually held numerous senior executive functions throughout her profession at both biotechnology and big pharmaceutical business.
“Aleksandra brings tested executive management abilities, deep translational and medical advancement proficiency, and the capability to be successful in both big and little business cultures,” stated Jeffrey Hatfield, ceo of Vividion. “Her addition to our group comes at an amazing inflection point for our development, as we plainly see the prospective to advance numerous programs into the center beginning next year.”
“I am really thrilled to sign up with Vividion to continue to advance development in an entrepreneurial environment concentrated on client advantages and results,” stated Dr. Rizo. “I’m satisfied by the pipeline’s breadth of unique, first-in-class programs in oncology and immunology. These programs are almost all targeting proteins the market has actually formerly considered as undruggable and suggest the prospective to provide massive worth to clients if effective. I am likewise captivated by the ingenious organization design developed with Bayer that permits us to run mainly autonomously and individually however with the technical knowledge and monetary stability of a significant pharmaceutical business.”
Dr. Rizo has actually served most just recently a